Nateglinide provides tighter glycaemic control than glyburide in patients with Type 2 diabetes with prevalent postprandial hyperglycaemia.

Trial Profile

Nateglinide provides tighter glycaemic control than glyburide in patients with Type 2 diabetes with prevalent postprandial hyperglycaemia.

Completed
Phase of Trial: Phase III

Latest Information Update: 24 Mar 2011

At a glance

  • Drugs Glibenclamide; Nateglinide
  • Indications Type 2 diabetes mellitus
  • Focus Therapeutic Use
  • Most Recent Events

    • 24 Mar 2011 Secondary endpoint '2h-plasma-glucose-level' has not been met
    • 24 Mar 2011 Primary endpoint 'Fasting-glucose-level' has not been met
    • 24 Mar 2011 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top